Navigation Links
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Date:10/17/2011

ified by the words such as, but not limited to, "intend," "expect," "estimate," "anticipate," "believe," "plan," "should," "may," "could," "will," "continue," and words or phrases of similar meaning.  As the forward-looking statements are based on the Company's current expectations, the Company cannot guarantee any related future results, levels of activity, performance or achievements.  All forward-looking statements included in this press release are based on management's assessment of information available to the Company on the date hereof or thereof and are subject to certain risks, uncertainties and assumptions.  The forward-looking statements reflect the Company's position as of the date they were made and the Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  Actual results may differ materially from those projected in such forward-looking statements for a number of reasons including, but not limited to, the following: our expectations regarding clinical trials, development timelines, future IND filings for new product candidates, and regulatory filings and submissions for any of our product candidates in clinical development; fluctuations in our operating results, in particular if EYLEA™ or any of our other late-stage product candidates is approved for marketing, and our revenues, market share, and/or market acceptance of EYLEA™ or such other products do not meet the expectations of investors or analysts; the possible success of any of our current or future product candidates; the determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize our product and drug candidates; pricing or reimbursement actions or decisions by government authorities or insurers affecting the coverage or reimbursement of any of our product ca
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
6. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
10. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Four-dimensional (4-D) printing develops materials that ... stimuli such as changes in temperature. This advanced ... in multiple industries.  In the near future, 4-D ... objects ranging from human organs to parts used ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
(Date:8/20/2014)... Aug. 20, 2014 Neurotrope, Inc. (OTCQB: ... conference call to provide an update on Company ... daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) or ... cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference replay ... through September 2, 2014 at (888) 203-1112 (U.S. ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... LA JOLLA, Calif., Jan. 13 Burnham ... an assay development and license agreement with ... L.L.C. (J&JPRD). The agreement is Burnham,s ... company.Under this multi-year agreement, Burnham will provide ...
... - GeneNews Limited (TSX: GEN), a company focused ... detection of diseases and personalized health management, today ... 7,473,528 entitled "Method for the detection of Chagas ... protects the Company,s discovery of a blood biomarker-based ...
... Datafarm, Inc. a leading provider of Electronic Document Publishing Solutions and ... announce the appointment of Mr. Daniel F. Orfe to Vice President, ... will oversee Datafarm,s Regulatory Services Group. , ... Marlborough, ...
Cached Biology Technology:Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform 2Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services 2Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services 3Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services 4
(Date:8/21/2014)... tube connectors, designed by an international standards process, will ... According to an invited review published in the OnlineFirst ... NCP ), the official journal of the American Society ... will greatly reduce the occurrence of misconnection that can ... connectors, which are used to join medical devices, components, ...
(Date:8/21/2014)... from North Carolina State University have developed a novel ... model has applications for creating new materials as well ... "Our new technique allows us to model much larger ... much more quickly," says Nan Li, lead author of ... in NC State,s Department of Materials Science and Engineering. ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
Breaking Biology News(10 mins):New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2Pica in pregnant teens linked to low iron 2
... WASHINGTON, D.C. (March 7, 2011) -- All our daily activities, ... on signals carried along the body,s vast network of neurons. ... small molecules within nerve cells -- receptors, ion channels, and ... recently, the study of these molecules in real time has ...
... gene that causes Hajdu-Cheney syndrome, a disorder of the ... The study, published in Nature Genetics today, ... highlights the gene as a potential target for treating ... reported cases of Hajdu-Cheney syndrome (HCS), of which severe ...
... separates from Greenland, is the calving due to typical ... called the Scalable, Efficient, and Accurate Community Ice Sheet ... Ridge National Laboratory, aims to use state-of-the-art simulation to ... climate. ORNL computational Earth scientist Kate Evans leads ...
Cached Biology News:Gene responsible for severe osteoporosis disorder discovered 2
... Rabbit Reticulocyte Lysate contains the cellular components ... acids, initiation, elongation and termination factors) but ... Untreated Lysate is used primarily for the ... abundant source of endogenous globin mRNA. Untreated ...
... All MagCellect Ferrofluid products perform ... with R&D Systems MagCellect Magnet. ... this neodymium iron boron permanent ... x 75 mm test tubes ...
... The ScriptCap™ 2'-O-Methyltransferase converts Cap 0 (or ... The Cap 1 structure has been shown ... up to 50%. This improvement is seen ... ScriptCap™ m7G Capping System as well as ...
Request Info...
Biology Products: